| Human chimeric antigen receptor macrophages for cancer immunotherapy M Klichinsky, M Ruella, O Shestova, XM Lu, A Best, M Zeeman, ... Nature biotechnology 38 (8), 947-953, 2020 | 1450 | 2020 |
| Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, ... Cancer discovery 5 (12), 1282-1295, 2015 | 1426 | 2015 |
| Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell M Ruella, J Xu, DM Barrett, JA Fraietta, TJ Reich, DE Ambrose, ... Nature medicine 24 (10), 1499-1503, 2018 | 722 | 2018 |
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ... The Journal of clinical investigation 126 (10), 3814-3826, 2016 | 673 | 2016 |
| Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ... Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014 | 577 | 2014 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ... Blood, The Journal of the American Society of Hematology 127 (9), 1117-1127, 2016 | 555 | 2016 |
| Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, ... Cell 173 (6), 1439-1453. e19, 2018 | 527 | 2018 |
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, ... Leukemia 29 (8), 1637-1647, 2015 | 526 | 2015 |
| Emerging cellular therapies for cancer S Guedan, M Ruella, CH June Annual review of immunology 37 (1), 145-171, 2019 | 433 | 2019 |
| An NK-like CAR T cell transition in CAR T cell dysfunction CR Good, MA Aznar, S Kuramitsu, P Samareh, S Agarwal, G Donahue, ... Cell 184 (25), 6081-6100. e26, 2021 | 381 | 2021 |
| Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies M Ruella, MV Maus Computational and structural biotechnology journal 14, 357-362, 2016 | 356 | 2016 |
| Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy EA Chong, M Ruella, SJ Schuster New England Journal of Medicine 384 (7), 673-674, 2021 | 355 | 2021 |
| Immunogenicity of CAR T cells in cancer therapy DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, ... Nature reviews Clinical oncology 18 (6), 379-393, 2021 | 312 | 2021 |
| Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses K Watanabe, Y Luo, T Da, S Guedan, M Ruella, J Scholler, B Keith, ... JCI insight 3 (7), e99573, 2018 | 311 | 2018 |
| Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction N Singh, YG Lee, O Shestova, P Ravikumar, KE Hayer, SJ Hong, XM Lu, ... Cancer discovery 10 (4), 552-567, 2020 | 306 | 2020 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 303 | 2022 |
| T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy G Ghilardi, JA Fraietta, JN Gerson, VM Van Deerlin, JJD Morrissette, ... Nature medicine 30 (4), 984-989, 2024 | 259 | 2024 |
| Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor J Brogdon, E Choi, HE Ebersbach, D Glass, H Huet, CH June, J Mannick, ... US Patent 10,174,095, 2019 | 244 | 2019 |
| The Addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma M Ruella, SS Kenderian, O Shestova, JA Fraietta, S Qayyum, Q Zhang, ... Clinical Cancer Research 22 (11), 2684-2696, 2016 | 219 | 2016 |
| Adoptive immunotherapy for cancer M Ruella, M Kalos Immunological reviews 257 (1), 14-38, 2014 | 210 | 2014 |
Carl JuneUniversity of PennsylvaniaVerified email at upenn.edu
